Caris Life Sciences Makes Nasdaq Debut

North Texas-based Caris Life Sciences, a pioneer in AI-driven cancer diagnostics, is now a publicly traded company. The Irving-headquartered biotech raised $494 million in its Nasdaq debut under the ticker CAI, with shares opening at $27 after being priced at $21—bringing its market cap to approximately $7.66 billion.

Founded in 2008 by David Halbert—motivated by his mother’s battle with cancer—Caris leverages artificial intelligence for advanced tissue- and blood-based molecular profiling to improve cancer diagnosis and treatment selection. 

Learn more